Hikma
From Wikipedia, the free encyclopedia
| Hikma Pharmaceuticals | |
 |
|
| Type | Public (LSE: HIK) |
|---|---|
| Founded | Amman, Jordan (1978) |
| Headquarters | Headquartered in London, UK |
| Key people | Samih Darwazah CEO Mazen Darwazah VC Taghreed Al-Shunnar VP |
| Industry | Pharmaceuticals |
| Products | Amoclan Prograf Suprax See complete products listing. |
| Revenue | £139,510,000 (2005) |
| Employees | 1,827 (2005) |
| Slogan | Quality Pharmaceuticals |
| Website | www.hikma.com |
Hikma Pharmaceuticals (LSE: HIK) is a publicly limited pharmaceutical manufacturing company that produces licenced and generic drugs. The firm was founded in Amman, Jordan in 1978, but is now headquartered in London. In August 1996, Hikma Pharmaceuticals became the first Arab company to export pharmaceutical products to the United States[1]. During 2005, the Group acquired the entire share capital of Hikma Pharma Ltd and Isitituto Biochimico Pavese Pharma.
[edit] Notes
[edit] External links
- Hikma Pharmaceuticals PLC Website - Official site
 |
This article about a medical, pharmaceutical or biotechnological corporation or company is a stub. You can help Wikipedia by expanding it. |
 |
This Jordan-related article is a stub. You can help Wikipedia by expanding it. |
 |
This article about a company of the UK is a stub. You can help Wikipedia by expanding it. |
